The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Investing.com -- Boston Scientific Corp (NYSE: BSX) dropped 10% Wednesday after Chief Executive Mike Mahoney indicated that standalone Watchman heart implant procedures continue to decline and ...

Add Yahoo as a preferred source to see more of our stories on Google. Boston Scientific’s Watchman FLX Pro device, the latest version of its left atrial appendage closure system, was approved by the ...

Boston Scientific cut its full-year outlook after two of its core heart-disease products faced unexpected challenges in the second quarter. Revenue from the Watchman heart implant, which is used to ...

Boston Scientific thinks Watchman represents a $500 million market opportunity, but how are physicians viewing the device now that reimbursement is available? Boston Scientific's left atrial appendage ...

Boston Scientific's WATCHMAN FLX Pro sits invisibly inside the heart, yet it promises something very tangible for many atrial fibrillation patients - protection from stroke without a lifetime on blood ...

Boston Scientific (BSX) stock tumbled to a two-year low Monday on mixed test results for its Watchman device in patients at risk of having a stroke. Watchman FLX involves a one-time, minimally ...

Boston Scientific (US10117L1017) is back in focus on the NYSE after management cut its 2026 guidance and several research houses lowered price targets for the medtech stock. The changes come as growth ...

17 deaths and 120 serious injuries have been reported due to complications during Watchman procedures. Boston Scientific warned Watchman customers of a higher risk of complications during procedures ...

May 27 (Reuters) - Boston Scientific shares sank to their lowest in over two years on Wednesday, after the medical device maker warned it was facing pressure due to softer uptake of its heart disease ...